5 products found
Biocartis NV Products
-
Idylla - Platform
The Idylla solution is a revolutionary, fully-automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time. It makes molecular testing fast, convenient and suitable for any lab.
-
Biocartis Idylla - Fully-Automated Real-Time PCR Based Molecular Testing System
The Idylla solution is a revolutionary, fully-automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time. It makes molecular testing fast, convenient and suitable for any ...
-
Idyllatm - Oncology Assays
Idylla offers assays for melanoma, colorectal and lung cancer.
-
Biocartis Idylla - Model BRAF - Fully Automated Mutation Test Covers System
The fully automated Idylla BRAF Mutation Test covers BRAF V600E, E2, D, K, R and M mutation with a sensitivity of 1% of mutant in wild type background in FFPE samples with an excellent concordance to reference methods of ...
-
Biocartis Idylla - Model EGFR - Fully Automated Mutation Test Covers System
The fully automated Idylla EGFR Mutation Test covers 51 mutations in exons 18–21 in a single cartridge using only 1 FFPE tissue section from metastatic NSCLC showing a high concordance of >95% compared with reference ...
-
Biocartis Idylla - Model KRAS - Fully Automated Mutation Test Covers System
The fully automated Idylla KRAS Mutation Test covers 21 KRAS mutations in exons 2,3 and 4 showing an excellent concordance to reference methods of >95%. Comparison with various other KRAS detecting technologies revealed a superior performance of the IdyllaTM KRAS Mutation Test in terms of ease of use, turnaround time, and hands-on time while demonstrating superior levels of ...
-
Biocartis - Model ctKRAS - Fully Automated Mutation Test Covers System
The fully automated Idylla ctKRAS Mutation Test is minimally invasive, fast and easy to perform and can be used as complement to tissue testing to determine the RAS mutation status at diagnosis. IdyllaTM ctKRAS covers 21 KRAS mutations in exons 2,3 and 4 and showed an high concordance to NGS of 96% using plasma samples from 198 mCRC patients enrolled in the prospective multicenter RASANC ...